These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 34853513)
41. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Das S; Ng WK; Tan RB Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358 [TBL] [Abstract][Full Text] [Related]
42. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546 [TBL] [Abstract][Full Text] [Related]
43. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization. Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427 [TBL] [Abstract][Full Text] [Related]
44. Microwave-assisted formulation of solid lipid nanoparticles loaded with non-steroidal anti-inflammatory drugs. Shah RM; Eldridge DS; Palombo EA; Harding IH Int J Pharm; 2016 Dec; 515(1-2):543-554. PubMed ID: 27789371 [TBL] [Abstract][Full Text] [Related]
45. Chitosan hydrogel for topical delivery of ebastine loaded solid lipid nanoparticles for alleviation of allergic contact dermatitis. Kazim T; Tariq A; Usman M; Ayoob MF; Khan A RSC Adv; 2021 Nov; 11(59):37413-37425. PubMed ID: 35496417 [TBL] [Abstract][Full Text] [Related]
46. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. Vivek K; Reddy H; Murthy RS AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544 [TBL] [Abstract][Full Text] [Related]
48. Solid lipid nanoparticles (SLNs) gels for topical delivery of aceclofenac in vitro and in vivo evaluation. Dasgupta S; Ghosh SK; Ray S; Mazumder B Curr Drug Deliv; 2013 Dec; 10(6):656-66. PubMed ID: 24274634 [TBL] [Abstract][Full Text] [Related]
49. Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits. El-Say KM; Hosny KM PLoS One; 2018; 13(8):e0203405. PubMed ID: 30161251 [TBL] [Abstract][Full Text] [Related]
50. Development and evaluation of coenzyme Q10 loaded solid lipid nanoparticle hydrogel for enhanced dermal delivery. Korkm E; Gokce EH; Ozer O Acta Pharm; 2013 Dec; 63(4):517-29. PubMed ID: 24451076 [TBL] [Abstract][Full Text] [Related]
51. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Youshia J; Kamel AO; El Shamy A; Mansour S Int J Nanomedicine; 2012; 7():2483-96. PubMed ID: 22679362 [TBL] [Abstract][Full Text] [Related]
53. Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles. Jia Y; Ji J; Wang F; Shi L; Yu J; Wang D Drug Deliv; 2016 May; 23(4):1317-25. PubMed ID: 25371296 [TBL] [Abstract][Full Text] [Related]
54. Central composite design-based optimization, fabrication, and pharmacodynamic assessment of sulfasalazine-loaded lipoidal nanoparticle-based hydrogel for the management of rheumatoid arthritis. Mishra R; Jain N; Kaul S; Nagaich U Drug Deliv Transl Res; 2023 Apr; 13(4):994-1011. PubMed ID: 36515863 [TBL] [Abstract][Full Text] [Related]
55. Targeting of eugenol-loaded solid lipid nanoparticles to the epidermal layer of human skin. Garg A; Singh S Nanomedicine (Lond); 2014; 9(8):1223-38. PubMed ID: 23987096 [TBL] [Abstract][Full Text] [Related]
56. Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Varia JK; Dodiya SS; Sawant KK Curr Drug Deliv; 2008 Jan; 5(1):64-9. PubMed ID: 18220553 [TBL] [Abstract][Full Text] [Related]
57. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis. Chokshi NV; Khatri HN; Patel MM Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392 [TBL] [Abstract][Full Text] [Related]
58. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Khalil RM; Abd-Elbary A; Kassem MA; Ghorab MM; Basha M Pharm Dev Technol; 2014 May; 19(3):304-14. PubMed ID: 23528038 [TBL] [Abstract][Full Text] [Related]
59. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation. Dudhipala N; Veerabrahma K Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472 [TBL] [Abstract][Full Text] [Related]
60. Topical phenytoin nanostructured lipid carriers: design and development. Motawea A; Borg T; Abd El-Gawad AEH Drug Dev Ind Pharm; 2018 Jan; 44(1):144-157. PubMed ID: 28956451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]